TMS for Suicidal Crisis in Active Duty SMs

Not Applicable

Completed

Conditions: Suicidal and Self-Injurious Behavior
Suicide
Suicidal Ideation
Suicidal Intention
Suicidal Depression
Suicidal Impulses

Interventions: Device: Neuronetics NeuroStar XPLOR magnetic stimulator - Active
Device: Neuronetics NeuroStar XPLOR magnetic stimulator - Sham

Brief Summary: The purpose of this study is to determine if the use of Transcranial Magnetic Stimulation (TMS) provides rapid reduction and sustained attenuation of suicidal crisis. TMS is a treatment for suicidal crisis that is quicker, less invasive, better tolerated, and with fewer side effects than current treatments such as Electroconvulsive Therapy (ECT) and medication therapies. There will be 6 months of follow-up, in order to establish the ongoing and lasting therapeutic effect of TMS.

Detailed Description: The programmatic-level objective of the study is to address the goals of the Army STARRS Program and the Suicide Prevention for America's Veterans Act through implementation of an effective acute treatment for patients psychiatrically admitted in suicidal crisis as well as other patients at high-risk for suicide. This is achieved by application of TMS, which provides a treatment for suicidal crisis that is quicker, less invasive, better tolerated, and with fewer side effects and less incapacitation than current treatments such as ECT and pharmacologic therapies. A recent study led by the senior consultant of this proposal demonstrated tolerance and efficacy for a new, high-dose regimen of TMS in a VA population with an average age of 47. The objective of the proposed study is to extend the application of TMS to a younger population of Active Duty Service Members (SM) in order to demonstrate efficacy for returning veterans of the Middle East wars, in particular, as well as the civilian young adult population. TMS dosage in the proposed study is recalibrated to commercially-standard levels in order to provide consistency with devices currently in clinical operation. In addition, follow-up in the proposed study continues for 6 months in order to establish persistence and durability of the therapeutic effect of TMS.

Recruitment & Eligibility

Inclusion Criteria

All Active Duty SMs (regardless of sex, ethnicity, sexual or religious orientation) who are admitted to Eisenhower Army Medical Center (EAMC) Inpatient Psychiatric Service (IPS) with active suicidality or elevated risk for suicide regardless of most psychiatric diagnostic co-morbidity (see exclusion criteria). This includes in-patient admissions for suicidality and outpatient SMs with a Columbia-Suicide Severity Rating Scale (C-SSRS) score ≥3.
Age 18 to 60
Able to speak and read English.

Exclusion Criteria

Combative with staff.
Comatose/catatonia.
Incapacity owing to active mania or psychosis.
Epilepsy, multiple sclerosis, or cerebrovascular accident.
Non-removable metal in the head (Shrapnel; plates, aneurysm coils/clips; metal tattoos etc.)
Implantable devices (pacemakers, stimulators, etc.)
Schizophrenic or borderline personality.
Positive screen for pregnancy.
Already receiving TMS as a treatment for depression.
Non-English reading and speaking subjects

Arm && Interventions

Group	Intervention	Description
TMS active	Neuronetics NeuroStar XPLOR magnetic stimulator - Active	Neuronetics NeuroStar XPLOR magnetic stimulator - Active; Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes. Treatment Dose: \~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC (Standard of Care).
TMS sham	Neuronetics NeuroStar XPLOR magnetic stimulator - Sham	Neuronetics NeuroStar XPLOR magnetic stimulator - Sham; Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.

Primary Outcome Measures

Name	Time	Method
Change in Suicidal Ideation (Acute)	Change over the active treatment course ie. the 3 days of active treatment	The Beck Scale for Suicidal Ideation (SSI-T) is a 19-item clinician administered scale measuring current suicide ideation (SSI-C), suicide ideation at its worst point in the patient's life (SSI-W), and degree of hopelessness. The scale has been well validated. SSI-T scores range from 0-38, with higher scores indicating greater suicide risk.

Secondary Outcome Measures